- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
AbbVie Shares Dip 1% After Insider Selling
Insider SVP David Ryan Purdue sold over $1.2 million in company stock
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Shares of pharmaceutical giant AbbVie (NYSE:ABBV) fell 1% on Monday after an insider sold a significant number of shares in the company. Specifically, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock at an average price of $233.56, for a total transaction of $1,221,518.80. This trade represents a 66.34% decrease in Purdue's ownership of the stock.
Why it matters
Insider selling can sometimes be a signal of potential issues or concerns within a company, even for large, established firms like AbbVie. While a single insider sale does not necessarily indicate broader problems, it can raise questions and impact investor sentiment, leading to a temporary dip in the stock price.
The details
The sale by SVP David Ryan Purdue occurred on March 4, 2026. Following the transaction, Purdue now directly owns 2,654 shares of AbbVie stock, valued at $619,868.24. The company's shares traded as low as $223.23 on Monday before closing at $227.7470, down 1% from the previous trading session.
- The insider sale occurred on March 4, 2026.
- AbbVie's shares fell 1% during mid-day trading on Monday, March 9, 2026.
The players
AbbVie Inc.
A global, research-driven biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions.
David Ryan Purdue
A senior vice president at AbbVie who sold over $1.2 million worth of the company's stock.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
While a single insider sale does not necessarily indicate broader problems at AbbVie, it can raise questions and impact investor sentiment, leading to a temporary dip in the stock price. Investors will be watching closely to see if this is an isolated incident or part of a larger trend.
